Alison Sawyer, MD
Endocrinology, Diabetes & Metabolism · Santa Fe, NMNPI 1164455663
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Insulet Corporation at 28.6% of the total. Reporting peaked in 2019 at $483 and has fallen 66.5% since, to $162 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NM, where the typical reported total is $1,943.
Across 101 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$544
- Novo Nordisk$213
- Medtronic$186
- Abbott$150
- Lilly USA, LLC$131
- Janssen Scientific Affairs, LLC$117
- plus $560 from 15 others
What the payments were for
- Food & beverage$1,88599%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 30 | $544 |
| Novo Nordisk | 16 | $213 |
| Medtronic(2 entities) | 4 | $186 |
| Abbott | 7 | $150 |
| Lilly USA, LLC | 7 | $131 |
| Janssen Scientific Affairs, LLC | 1 | $117 |
| AstraZeneca | 6 | $86 |
| Amgen | 4 | $68 |
| Acella Pharmaceuticals, LLC | 3 | $64 |
| Johnson & Johnson | 7 | $59 |
| Dexcom, Inc. | 3 | $58 |
| Boehringer Ingelheim | 2 | $41 |
| Pfizer | 2 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Aegerion Pharmaceuticals, Inc. | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| Merck | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$138
- Omnipod$132
- INVOKANA$117
- XARELTO$117
How this compares
$1,902 in reported general payments places this provider in the 45th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 438 | $532,925 |
| OzempicSemaglutide | 189 | $232,660 |
| Tresiba Flextouch U-200Insulin Degludec | 109 | $115,663 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 91 | $110,280 |
| Xigduo XrDapaglifloz Propaned/Metformin | 72 | $90,814 |
| JardianceEmpagliflozin | 95 | $88,049 |
| TymlosAbaloparatide | 27 | $78,794 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 79 | $78,789 |
| TrulicityDulaglutide | 51 | $76,042 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $54,542 |
| Humalog Kwikpen U-200Insulin Lispro | 44 | $42,024 |
| FarxigaDapagliflozin Propanediol | 35 | $39,959 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $39,923 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $38,099 |
| ProliaDenosumab | 19 | $33,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $131 | $629,758578 claims |
| Novo NordiskOzempic, Novolog | $213 | $247,702259 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $41 | $166,838174 claims |
| Radius Health, Inc.Tymlos | $19 | $78,79427 claims |
| MerckJanumet Xr, Januvia | $14 | $50,12332 claims |
| AstraZenecaFarxiga | $86 | $39,95935 claims |
| AmgenProlia | $68 | $33,24019 claims |
| PfizerGenotropin | $38 | $14,54820 claims |
| Sanofi-aventis U.S. LLCAdmelog | $13 | $9,71515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
Other endocrinology, diabetes & metabolism in Santa Fe
- Robert BernsteinSanta Fe$158
- Robert FerraroAlbuquerque$101K
- Rina Patel TrujilloAlbuquerque$100K
- Jeremy GleesonAlbuquerque$46K
- David SchadeAlbuquerque$16K
- Mansi MehtaAlbuquerque$15K
- Matthew BouchonvilleAlbuquerque$7K
- Teodor DuroAlbuquerque$6K
- Andrew LancasterAlamogordo$6K
- Ivan PinonAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.